Muscarinic receptors: Their distribution and function in body systems, and the implications for treating overactive bladder

British Journal of Pharmacology

Volumn 148, Issue 5, 2006, Pages 565-578

  Abrams, Paul ^a   Andersson, Karl Erik ^b   Buccafusco, Jerry J ^c   Chapple, Christopher ^d   De Groat, William Chet ^e   Fryer, Alison D ^f   Kay, Gary ^g   Laties, Alan ^h   Nathanson, Neil M ⁱ   Pasricha, Pankaj Jay ^j   Wein, Alan J ^h  

^a SOUTHMEAD HOSPITAL   (United Kingdom)

^b LUND UNIVERSITY HOSPITAL   (Sweden)

^c MEDICAL COLLEGE OF GEORGIA   (United States)

^d ROYAL HALLAMSHIRE HOSPITAL   (United Kingdom)

^e UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

^f OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

^g Washington Neuropsychological Institute   (United States)

^h UNIVERSITY OF PENNSYLVANIA   (United States)

ⁱ UNIVERSITY OF WASHINGTON   (United States)

^j UNIVERSITY OF TEXAS MEDICAL BRANCH   (United States)

more..

Author keywords

Antimuscarinics; Bladder; Brain; Eye; Gastrointestinal tract; Heart; Muscarinic receptors; Overactive bladder; Salivary glands; Selective M 3 antagonists

Indexed keywords

DARIFENACIN; DICYCLOVERINE; FLAVOXATE; IMIPRAMINE; MUSCARINIC M1 RECEPTOR AGONIST; MUSCARINIC M3 RECEPTOR; MUSCARINIC RECEPTOR; MUSCARINIC RECEPTOR BLOCKING AGENT; ORPHENADRINE; OXYBUTYNIN; PROPANTHELINE BROMIDE; PROPIVERINE; SOLIFENACIN; TEMIVERINE; TERODILINE; TOLTERODINE; TRIHEXYPHENIDYL; TROSPIUM CHLORIDE;

ALZHEIMER DISEASE; BRAIN; CARDIOTOXICITY; CLINICAL TRIAL; CONSTIPATION; DETRUSOR MUSCLE; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG DISTRIBUTION; DRUG EFFECT; DRUG EFFICACY; DRUG HALF LIFE; DRUG PROTEIN BINDING; DRUG RECEPTOR BINDING; EYE; GASTROINTESTINAL TRACT; HEART; HUMAN; MUSCLE CONTRACTION; NONHUMAN; OVERACTIVE BLADDER; PATHOPHYSIOLOGY; PRIORITY JOURNAL; PROTEIN LOCALIZATION; RECEPTOR INTRINSIC ACTIVITY; REVIEW; RISK BENEFIT ANALYSIS; SALIVARY GLAND; SENSORY NERVE; TORSADE DES POINTES; UROTHELIUM; XEROSTOMIA;

ANIMALS; DOSE-RESPONSE RELATIONSHIP, DRUG; HUMANS; MODELS, BIOLOGICAL; MUSCARINIC ANTAGONISTS; RECEPTOR, MUSCARINIC M3; RECEPTORS, MUSCARINIC; TISSUE DISTRIBUTION; URINARY BLADDER, OVERACTIVE;

EID: 33745602006     PISSN: 00071188     EISSN: 14765381     Source Type: Journal    
DOI: 10.1038/sj.bjp.0706780     Document Type: Review

References (151)

1. ABDEL-RAHMAN, A., SHETTY, A.K. & ABOU-DONIA, M.B. (2002). Disruption of the blood-brain barrier and neuronal cell death in cingulate cortex, dentate gyrus, thalamus, and hypothalamus in a rat model of Gulf-War syndrome. Neurobiol. Dis., 10, 306-326.
2. ABRAMS, P., CARDOZO, L., FALL, M., GRIFFITHS, D., ROSIER, P., ULMSTEN, U., VAN KERREBROECK, P., VICTOR, A. & WEIN, A. (2002). The standardisation of terminology of lower urinary tract function: report from the standardisation sub-committee of the International Continence Society. Neurourol. Urodyn., 21, 167-178.
3. 1 muscarinic receptor mutant mice. Nat. Neurosci., 6, 51-58.
4. ANDERSON, R.U., MOBLEY, D., BLANK, B., SALTZSTEIN, D., SUSSET, J. & BROWN, J.S. (1999). Once daily controlled versus immediate release oxybutynin chloride for urge urinary incontinence. J. Urol., 161, 1809-1812.
5. ANDERSSON, K.-E. (1984). Clinical pharmacology of terodiline. Scand. J. Urol. Nephrol. Suppl., 87, 13-20.
6. ANDERSSON, K.-E. (1988). Current concepts in the treatment of disorders of micturition. Drugs, 35, 477-494.
7. ANDERSSON, K.-E. (2004). Antimuscarinics for treatment of overactive bladder. Lancet Neurol., 3, 46-53.
8. ANDERSSON, K.E., APPELL, R., AWAD, S., CHAPPLE, C., DRUTZ, H., FINKBEINER, A., HAAB, F. & VELA NAVARRETE, R. (2002). Pharmacological treatment of urinary incontinence. In: Incontinence, 2nd International Consultation on Incontinence, ed. Abrams, P., Cardozo, L., Khoury, S. & Wein, A., pp. 479-511. Plymouth, U.K.: Plymbridge Distributors Ltd.
9. ANDERSSON, K.-E., APPELL, R., CARDOZO, L., CHAPPLE, C., DRUTZ, H., FOURCROY, J., VELA NAVARETTE, R., NISHIZAWA, O. & WEIN, A. (2005). Pharmacological treatment of urinary incontinence. In: Incontinence, 3rd International Consultation on Incontinence. ed. Abrams, P., Khoury, S. & Wein, A., Editions 21, pp. 811-854. France: Health Publication Ltd.
10. ANDERSSON, K.-E., APPELL, R., CARDOZO, L.D., CHAPPLE, C., DRUTZ, H.P., FINKBEINER, A.E., HAAB, F. & VELA NAVARRETE, R. (1999). The pharmacological treatment of urinary incontinence. BJU Int., 84, 923-947.
11. ANDERSSON, K.E. & CHAPPLE, C.R. (2001). Oxybutynin and the overactive bladder. World J. Urol., 19, 319-323.
12. ANDERSSON, K.-E. & YOSHIDA, M. (2003). Antimuscarinics and the overactive detrusor - which is the main mechanism of action? Eur. Urol., 43, 1-5.
13. APPELL, R.A., ABRAMS, P., DRUTZ, H.P., VAN KERREBROECK, P., MILLARD, R. & WEIN, A. (2001). Treatment of overactive bladder: long-term tolerability and efficacy of tolterodine. World J. Urol., 19, 141-147.
14. APPELL, R.A., CHANCELLOR, M.B., ZOBRIST, R.H., THOMAS, H. & SANDERS, S.W. (2003). Pharmacokinetics, metabolism, and saliva output during transdermal and extended-release oral oxybutynin administration in healthy subjects. Mayo Clin. Proc., 78, 696-702.
15. ARMSTRONG, R.B., LIBER, K.M. & PETERS, K.M. (2005). Comparison of dry mouth in women treated with extended-release formulations of oxybutynin or tolterodine for overactive bladder. Int. Urol. Nephrol., 37, 247-252.
16. BALLABH, P., BRAUN, A. & NEDERGAARD, M. (2004). The blood-brain barrier: an overview: structure, regulation, clinical implications. Neurobiol. Dis., 16, 1-13.
17. BARKIN, J., CORCOS, J., RADOMSKY, S., JAMMAL, M.-P., MICELI, P.C., REIZ, J.L., HARSANYI, Z. & DARKE, AC. (2004). A randomized, double-blind, parallel-group comparison of controlled- and immediate-release oxybutynin chloride in urge urinary incontinence. Clin. Ther., 26, 1026-1036.
18. BAUM, B.J. (1993). Principles of saliva secretion. Ann. N. Y. Acad. Sci., 694, 17-23.
19. BEROUKAS, D., GOODFELLOW, R., HISCOCK, J., JONSSON, R., GORDON, T.P. & WATERMAN, S.A. (2002). Up-regulation of M3-muscarinic receptors in labial salivary gland acini in primary Sjögren's syndrome. Lab. Invest., 82, 203-210.
20. BIRDER, L.A., BARRICK, S.R., ROPPOLO, J.R., KANAI, A.J., DEGROAT, W.C., KISS, S. & BUFFINGTON, C.A. (2003). Feline interstitial cystitis results in mechanical hypersensitivity and altered ATP release from the bladder urothelium. Am. J. Physiol. Renal. Physiol., 285, F423-F429.
21. BODICK, N.C., OFFEN, W.W., LEVEY, A.I., CUTLER, N.R., GAUTHIER, S.G., SATLIN, A., SHANNON, H.E., TOLLEFSON, G.D., RASMUSSEN, K., BYMASTER, F.P., HURLEY, D.J., POTTER, W.Z. & PAUL, S.M. (1997). Effects of xanomeline, a selective muscarinic receptor agonist, on cognitive function and behavioral symptoms in Alzheimer disease. Arch. Neurol., 54, 465-473.
22. 4 subtypes mediates the contraction of the rabbit iris sphincter. Naunyn-Schmiedeberg's Arch. Pharmacol., 345, 611-618.
23. BOGNAR, I.T., WESNER, M.T. & FUDER, H. (1990). Muscarinic receptor types mediating autoinhibition of acetylcholine release and sphincter contraction in the guinea-pig iris. Naunyn-Schmiedeberg's Arch Pharmacol., 341, 22-29.
24. 2 muscarinic receptor contributes to contraction of the denervated rat urinary bladder. Am. J. Physiol., 275, R1654-R1660.
25. 2. Am. J. Physiol. Regul. Integr. Comp. Physiol., 285, R701-R708.
26. BYMASTER, F.P., CARTER, P.A., YAMADA, M., GOMEZA, J., WESS, J., HAMILTON, S.E., NATHANSON, N.M., MCKINZIE, D.L. & FELDER, C.C. (2003). Role of specific muscarinic receptor subtypes in cholinergic parasympathomimetic responses, in vivo phosphoinositide hydrolysis, and pilocarpine-induced seizure activity. Eur. J. Neurosci., 17, 1403-1410.
27. CAULFIELD, M.P. (1993). Muscarinic receptors - characterization, coupling and function. Pharmacol. Ther., 58, 319-379.
28. CAULFIELD, M.P. & BIRDSALL, N.J.M. (1998). International union of pharmacology. XVII. Classification of muscarinic acetylcholine receptors. Pharmacol. Rev., 50, 279-290.
29. CHAPPLE, C.R. (2000). Muscarinic receptor antagonists in the treatment of overactive bladder. Urology., 55 (Suppl. 5A), 33-46.
30. CHAPPLE, C.R. (2001). Tolterodine once daily: selectivity for the bladder over effects on salivation compared to Ditropan XL. J. Urol., 165 (5 Suppl), 253 (Abstract 1040).
31. 3 selective receptor antagonist, in the treatment of overactive bladder. BJU Int., 95, 993-1001.
32. CHAPPLE, C.R. & ABRAMS, P. (2005). Comparison of darifenacin and oxybutynin in patients with overactive bladder: assessment of ambulatory urodynamics and impact on salivary flow. Eur. Urol., 48, 102-109.
33. CHESS-WILLIAMS, R. (2002). Muscarinic receptors of the urinary bladder: detrusor, urothelial and prejunctional. Auton. Autacoid. Pharmacol., 22, 133-145.
34. 3-receptors mediate contraction of human detrusor muscle in vitro. J. Auton. Pharmacol., 21, 243-248.
35. CHIBA, T., BHARUCHA, A.E., THOMFORDE, G.M., KOST, L.J. & PHILLIPS, S.F. (2002). Model of rapid gastrointestinal transit in dogs: effects of muscarinic antagonists and a nitric oxide synthase inhibitor. Neurogastroenterol. Motil., 14, 535-541.
36. CHOPPIN, A. & EGLEN, R.M. (2001). Pharmacological characterization of muscarinic receptors in dog isolated ciliary and urinary bladder smooth muscle. Br. J. Pharmacol., 132, 835-842.
37. CHU, F.M., DMCHOWSKI, R.R., LAMA, D.J., ANDERSON, R.U. & SAND, P.K. (2005). Extended-release formulations of oxybutynin and tolterodine exhibit similar central nervous system tolerability profiles: a subanalysis of data from the OPERA trial. Am. J. Obstet. Gynecol., 192, 1849-1854.
38. CLAXTON, A.J., CRAMER, J. & PIERCE, C. (2001). A systematic review of the associations between dose regimens and medication compliance. Clin. Ther., 23, 1296-1310.
39. CLEMETT, D. & JARVIS, B. (2001). Tolterodine: a review of its use in the treatment of overactive bladder. Drugs Aging, 18, 277-304.
40. COLECRAFT, H.M., EGAMINO, J.P., SHARMA, V.K. & SHEU, S.-S. (1998). Signaling mechanisms underlying muscarinic receptor-mediated increase in contraction rate in cultured heart cells. J. Biol. Chem., 273, 32158-32166.
41. COLLISON, D.J., COLEMAN, R.A., JAMES, R.S., CAREY, J. & DUNCAN, G. (2000). Characterization of muscarinic receptors in human lens cells by pharmacologic and molecular techniques. Invest. Ophthalmol. Vis. Sci., 41, 2633-2641.
42. 3 receptors regulate exocrine secretion by mucous acini. Am. J. Physiol. Cell Physiol., 271, C1963-C1972.
43. DE GROAT, W.C. (1997). A neurologic basis for the overactive bladder. Urology, 50 (Suppl. 6A), 36-52.
44. DHEIN, S., VAN KOPPEN, C.J. & BRODDE, O.-E. (2001). Muscarinic receptors in the mammalian heart. Pharmacol. Res., 44, 161-182.
45. DIEFENBACH, K., DONATH, F., MAURER, A., BRAVO, S.Q., WERNECKE, K.-D., SCHWANTES, U., HASELMANN, J. & ROOTS, I. (2003). Randomised, double-blind study of the effects of oxybutynin, tolterodine, trospium chloride and placebo on sleep in healthy young volunteers. Clin. Drug. Invest., 23, 395-404.
46. DIOKNO, A.C., APPELL, R.A., SAND, P.K., DMOCHOWSKI, R.R., GBUREK, B.M., KLIMBERG, I.W. & KELL, S.H. (2003). Prospective, randomized, double-blind study of the efficacy and tolerability of the extended-release formulations opf oxybutynin and tolterodine for overactive bladder: results of the OPERA trial. Mayo Clin. Proc., 78, 687-695.
47. 3 muscarinic acetylcholine receptors in human atrial myocytes: influence of chronic atrial fibrillation [abstract]. Naunyn-Schmiedeberg's Arch. Pharmacol., 367 (Suppl. 1), R94.
48. DONNELLAN, C.A., FOOK, L. & PLAYFER, J.R. (1997). Oxybutynin and cognitive dysfunction. BMJ, 315, 1363-1364.
49. DOUCHAMPS, J., DERENNE, F., STOCKIS, A., GANGJI, D., JUVENT, M. & HERCHUELZ, A. (1988). The pharmacokinetics of oxybutynin in man. Eur. J. Clin. Pharmacol., 35, 515-520.
50. DUVVURI, S., MAJUMAR, S. & MITRA, A.K. (2003). Drug delivery to the retina: challenges and opportunities. Expert Opin. Biol. Ther., 3, 45-56.
51. EGLEN, R.M. (2001). Muscarinic receptors and gastrointestinal tract smooth muscle function. Life Sci., 68, 2573-2578.
52. 3 receptors in guinea-pig ileum and atria in vitro. Br. J. Pharmacol., 109, 946-952.
53. 2 muscarinic receptor mediates contraction through indirect mechanisms in mouse urinary bladder. J. Pharmacol. Exp. Ther., 313, 368-378.
54. ESPOSITO, P., GHEORGHE, D., KANDERE, K., PANG, X., CONNOLLY, R., JACOBSON, S. & THEOHARIDES, T.C. (2001). Acute stress increases permeability of the blood-brain-barrier through activation of brain mast cells. Brain Res., 888, 117-127.
55. 3 muscarinic receptors mediate contraction of human urinary bladder. Br. J. Pharmacol., 136, 641-643.
56. 1 muscarinic agonists can modulate some of the hallmarks in Alzheimer's disease. J. Mol. Neurosci., 20, 349-356.
57. FRY, C.H., IKEDA, Y., HARVEY, R., WU, C. & SUI, G.-P. (2004). Control of bladder function by peripheral nerves: avenues for novel drug targets. Urology, 63 (Suppl. 3A), 24-31.
58. 3 muscarinic receptor single-and double-knockout mice. Mol. Pharmacol., 66, 260-267.
59. GERSHON, M.D. (2003). Serotonin and its implication for the management of irritable bowel syndrome. Rev. Gastroenterol. Disord., 3 (Suppl. 2), S25-S34.
60. GIL, D.W., KRAUSS, H.A., BOGARDUS, A.M. & WOLDEMUSSIE, E. (1997). Muscarinic receptor subtypes in human iris-ciliary body measured by immunoprecipitation. Invest. Ophthalmol. Vis. Sci., 38, 1434-1442.
61. GILLBERG, P.G., SUNDQUIST, S. & NILVEBRANT, L. (1998). Comparison of the in vitro and in vivo profiles of tolterodine with those of subtype-selective muscarinic receptor antagonists. Eur. J. Pharmacol., 349, 285-292.
62. GILLESPIE, J.I. (2004a). The autonomous bladder: a view of the origin of bladder overactivity and sensory urge. BJU Int., 93, 478-483.
63. GILLESPIE, J.I. (2004b). Modulation of autonomous contractile activity in the isolated whole bladder of the guinea pig. BJU Int., 93, 393-400.
64. GILLESPIE, J.I., HARVEY, I.J. & DRAKE, M.J. (2003). Agonist- and nerve-induced phasic activity in the isolated whole bladder of the guinea pig: evidence for two types of bladder activity. Exp. Physiol., 88, 343-357.
65. GOMEZ, A., MARTOS, F., BELLIDO, I., MARQUEZ, E., GARCIA, A.J., PAVIA, J. & DE LA CUESTA, F.S. (1992). Muscarinic receptor subtypes in human and rat colon smooth muscle. Biochem. Pharmacol., 43, 2413-2419.
66. GOMEZA, J., SHANNON, H., KOSTENIS, E., FELDER, C., ZHANG, L., BRODKIN, J., GRINBERG, A., SHENG, H. & WESS, J. (1999). Pronounced pharmacologic deficits in M2 muscarinic acetylcholine receptor knockout mice. Proc. Natl. Acad. Sci. U.S.A., 96, 1692-1697.
67. GOSLING, J.A., DIXON, J.S. & JEN, P.Y. (1999). The distribution of noradrenergic nerves in the human lower urinary tract: a review. Eur. Urol., 36 (Suppl. 1), 23-30.
68. GUPTA, S.K. & SATHYAN, G. (1999). Pharmacokinetics of an oral once-a-day controlled-release oxybutynin formulation compared with immediate-release oxybutynin. J. Clin. Pharmacol., 39, 289-296.
69. 3 selective receptor antagonist, is an effective and well-tolerated once-daily treatment for overactive bladder. Eur. Urol., 45, 420-429.
70. HABGOOD, M.D., BEGLEY, D.J. & ABBOTT, N.J. (2000). Determinants of passive drug entry into the central nervous system. Cell Mol. Neurobiol., 20, 231-253.
71. HALASKA, M., RALPH, G., WIEDEMANN, A., PRIMUS, G., BALLERING-BRÜHL, B., HÖFNER, K. & JONAS, U. (2003). Controlled, double-blind, multicentre clinical trial to investigate long-term tolerability and efficacy of trospium chloride in patients with detrusor instability. World J. Urol., 20, 392-399.
72. 1 muscarinic acetylcholine receptor. J. Pharmacol. Exp. Ther., 301, 129-137.
73. 3 muscarinic receptors in the urinary bladder of rats in vitro and in vivo. Br. J. Pharmacol., 120, 1409-1418.
74. HEGDE, S.S. & EGLEN, R.M. (1999). Muscarinic receptor subtypes modulating smooth muscle contractility in the urinary bladder. Life Sci., 64, 419-428.
75. 3 receptor subtype gene expression in the human heart. Cell Mol. Life Sci., 57, 175-180.
76. HULME, E.C., BIRDSALL, N.J.M. & BUCKLEY, N.J. (1990). Muscarinic receptor subtypes. Ann. Rev. Pharmacol. Toxicol., 30, 633-673.
77. 3 receptors. J Urol., 172, 2460-2464.
78. 3 receptor antagonism by the novel antimuscarinic agent solifenacin in the urinary bladder and salivary gland. Naunyn-Schmiedeberg's Arch Pharmacol., 366, 97-103.
79. ISHIZAKA, N., NODA, M., YOKOYAMA, S., KAWASAKI, K., YAMAMOTO, M. & HIGASHIDA, H. (1998). Muscarinic acetylcholine receptor subtypes in the human iris. Brain Res., 787, 344-347.
80. 1 receptor activation reduces maximum upstroke velocity of action potential in mouse right atria. Eur. J. Pharmacol., 346, 227-236.
81. 2-type muscarinic receptors mediate prejunctional inhibition of norepinephrine release in the human iris-ciliary body. Exp. Eye. Res., 58, 175-180.
82. KANNO, H., HORIKAWA, Y., HODGES, R.R., ZOUKHRI, D., SHATOS, M.A., RIOS, J.D. & DARTT, D.A. (2003). Cholinergic agonists transactivate EGFR and stimulate MAPK to induce goblet cell secretion. Am. J. Physiol. Cell Physiol., 284, C988-C998.
83. KATZ, I.R., SANDS, L.P., BILKER, W., DIFILIPPO, S., BOYCE, A. & D'ANGELO, K. (1998). Identification of medications that cause cognitive impairment in older people: the case of oxybutynin chloride. J. Am. Geriatr. Soc., 46, 8-13.
84. 3 selective antagonist for the treatment of overactive bladder, in healthy volunteers. BJU Int., 96, 1055-1062.
85. KERR, P.M., HILLIER, K., WALLIS, R.M. & GARLAND, C.J. (1995). Characterization of muscarinic receptors mediating contractions of circular and longitudinal muscle of human isolated colon. Br. J. Pharmacol., 115, 1518-1524.
86. 3 muscarinic receptors in the rat urinary bladder following partial outlet obstruction. J. Urol., 161, 1644-1650.
87. 3 receptors in response to acetylcholine. Arterioscler. Thromb. Vasc. Biol., 24, 1253-1258.
88. LI, M., JOHNSON, C.P., ADAMS, M.B. & SARNA, S.K. (2002). Cholinergic and nitrergic regulation of in vivo giant migrating contractions in rat colon. Am. J. Physiol. Gastrointest. Liver. Physiol., 283, G544-G552.
89. LIEBSCH, R., KORNHUBER, M.E., DIETL, D., GRÄFIN VON EINSIEDEL, H. & CONRAD, B. (1996). Blood-CSF barrier integrity in multiple sclerosis. Acta Neurol. Scand., 94, 404-410.
90. LIPTON, R.B., KOLODNER, K. & WESNES, K. (2005). Assessment of cognitive function of the elderly population: effects of darifenacin. J. Urol., 173, 493-498.
91. 3 muscarinic receptors in sublingual glands. Am. J. Physiol. Cell Physiol., 280, C884-C896.
92. 3 muscarinic acetylcholine receptors are devoid of cholinergic smooth muscle contractions but still viable. J. Neurosci., 22, 10627-10632.
93. 3 subtype. Proc. Natl. Acad. Sci. U.S.A., 97, 9579-9584.
94. 1 muscarinic receptors in representational memory. Neurosci. Lett., 116, 184-189.
95. 3 receptor subtype [abstract]. Neurourol. Urodyn., 21, A445.
96. NIIHASHI, M., ESUMI, M., KUSUMI, Y., SATO, Y. & SAKURAI, I. (2000). Expression of muscarinic receptor genes in the human coronary artery. Angiology., 51, 295-300.
97. NISHIMARU, K., TANAKA, Y., TANAKA, H. & SHIGENOBU, K. (2000). Positive and negative inotropic effects of muscarinic receptor stimulation in mouse left atria. Life Sci., 66, 607-615.
98. OLSSON, B. & SZAMOSI, J. (2001). Multiple dose pharmacokinetics of a new once daily extended release tolterodine formulation versus immediate release tolterodine. Clin. Pharmacokinet., 40, 227-235.
99. PAKULSKI, C., DROBNIK, L. & MILLO, B. (2000). Age and sex as factors modifying the function of the blood-cerebrospinal fluid barrier. Med. Sci. Monit., 6, 314-318.
100. PERRY, E.K., KILFORD, L., LEES, A.J., BURN, D.J. & PERRY, R.H. (2003). Increased Alzheimer pathology in Parkinson's disease related to antimuscarinic drugs. Ann Neurol., 54, 235-238.
101. PIETZKO, A., DIMPFEL, W., SCHWANTES, U. & TOPFMEIER, P. (1994). Influences of trospium chloride and oxybutynin on quantitative EEG in healthy volunteers. Eur. J. Clin. Pharmacol., 47, 337-343.
102. 3-muscarinic receptors in ventricular cardiomyocytes of adult rats. Br. J. Pharmacol., 138, 156-160.
103. 2 muscarinic receptor mediates in vitro bladder contractions from patients with neurogenic bladder dysfunction. Am. J. Physiol. Regul. Integr. Comp. Physiol., 286, R874-R880.
104. POYER, J.F., GABELT, B.T. & KAUFMAN, P.L. (1994). The effect of muscarinic agonists and selective receptor subtype antagonists on the contractile response of the isolated Rhesus monkey ciliary muscle. Exp. Eye Res., 59, 729-736.
105. PRESCRIBING INFORMATION (2004). Sanctura trospium chloride 20 mg tablets, http://www.sanctura.com/Sanctura_Prescribing_Information.pdf.
106. PRESCRIBING INFORMATION, VESICARE (US) (2004) http://www.vesicare.com/ pdf/vesica represcribing_info.pdf.
107. PRODUCT INFORMATION, DETROL (US) (2005) http://www.pfizer.com/download/ uspi_detrol.pdf.
108. PRODUCT INFORMATION, DETROL LA (US) (2005) http://pfizer.com/pfizer/ download/uspi_detrol_la.pdf.
109. PRODUCT INFORMATION, ENABLEX (US) (2005) http://www.pharma.us.novartis. com/product/pi/pdf/enablex.pdf.
110. PRODUCT INFORMATION, DITROPAN (US) (2005) http://www.ditropanxl.com/ professional/full_presc.htm.
111. PRODUCT INFORMATION. DITROPAN/DITROPAN XL (2004) http://www.orthomcneil. com/products/pi/pdfs/Lg%20Ditropan%20PI.pdf, http://www.orthomcneil.com/ products/pi/pdfs/ditropanxl.pdf.
112. RICHTER, A., ANTON, S.E., KOCH, P. & DENNETT, S.L. (2003). The impact of reducing dose frequency on health outcomes. Clin. Ther., 25, 2307-2335.
113. RODEN, D.M. (2004). Drug-induced prolongation of the QT interval. N. Engl. J. Med., 350, 1013-1022.
114. 2 muscarinic acetylcholine receptor knock-out mice show deficits in behavioral flexibility, working memory, and hippocampal plasticity. J. Neurosci., 24, 10117-10127.
115. 1 selective receptor antagonist for the treatment of overactive bladder. J. Clin. Pharm., 45, 1038-1047.
116. SHADE, D.L., CLARK, A.F. & PANG, I.-H. (1996). Effects of muscarinic agents on cultured human trabecular meshwork cells. Exp. Eye Res., 62, 201-210.
117. SMULDERS, R.A., KRAUWINKEL, W.J., SWART, P.J. & HUANG, M. (2004). Pharmacokinetics and safety of solifenacin succinate in healthy young men. J. Clin. Pharmacol., 44, 1023-1033.
118. SO, I., YANG, D.K., KIM, H.J., MIN, K.W., KANGE, T.M., KIM, S.J., KIM, K.W., PARTK, K.H., JEON, J.H., CHOI, K.H. & KIM, I.G. (2003). Five subtypes of muscarinic receptors are expressed in gastric smooth muscles of guinea pig. Exp. Mol. Med., 35, 46-52.
119. SOMOGYI, G.T. & DE GROAT, W.C. (1999). Function, signal transduction mechanisms and plasticity of presynaptic muscarinic receptors in the urinary bladder. Life Sci., 64, 411-418.
120. 1 muscarinic receptor -induced facilitation of ACh and noradrenaline release in the rat bladder is mediated by protein kinase C. J. Physiol., 496, 245-254.
121. SOMOGYI, G.T., ZERNOVA, G.V., YOSHIYAMA, M., ROCHA, J.N., SMITH, C.P. & DE GROAT, W.C. (2003). Change in muscarinic modulation of transmitter release in the rat urinary bladder after spinal cord injury. Neurochem. Int., 43, 73-77.
122. STARR, J.M., WARDLAW, J., FERGUSON, K., MACLULLICH, A., DEARY, I.J. & MARSHALL, I. (2003). Increased blood-brain barrier permeability in type II diabetes demonstrated by gadolinium magnetic resonance imaging. J. Neurol. Neurosurg. Psychiatry., 74, 70-76.
123. 3 selective receptor antagonist. BJU Int., 95, 580-586; Erratum in: BJU Int., 95, 1385-1386.
124. 4 receptor knockout mice: muscarinic receptor function in cardiac and smooth muscle in vitro. J. Pharmacol. Exp. Ther., 292, 877-885.
125. 3-receptor knockout mice: muscarinic receptor function in atria, stomach fundus, urinary bladder, and trachea. Am. J. Physiol. Regut. Integr. Comp. Physiol., 282, R1443-R1449.
126. STEVENS, L., CHAPPLE, C.R., TOPHILL, P. & CHESS-WILLIAMS, R. (2004a). A comparison of muscarinic receptor-mediated function in the normal and the neurogenic overactive bladder. J Urol., 171, 143 (Abstract 535).
127. STEVENS, L., CHESS-WILLIAMS, R. & CHAPPLE, C.R. (2004b). Muscarinic receptor function in the idiopathic overactive bladder. J Urol., 171, 140-141 (Abstract 527).
128. THIEME, H., HILDEBRANDT, J., CHORITZ, L., STRAUSS, O. & WIEDERHOLT, M. (2001). Muscarinic receptors of the M2 subtype in human and bovine trabecular meshwork. Graefe's Arch. Clin. Exp. Ophthalmol., 239, 310-315.
129. THOMAS, S., ROMANZI, L. & LHERITIER, K. (2005). Constipation and associated intervention in patients with overactive bladder treated with darifenacin or tolterodine. Int. Urogynecol. J., 16 (Suppl. 2), S101 (Abstract 306).
130. TOBIN, G. (2002). Presynaptic muscarinic receptor mechanisms and submandibular responses to stimulation of the parasympathetic innervation in bursts in rats. Auton. Neurosci., 99, 111-118.
131. TOBIN, G., GIGLIO, D. & GÖTRICK, B. (2002). Studies of muscarinic receptor subtypes in salivary gland function in anaesthetized rats. Auton. Neurosci., 100, 1-9.
132. 4-receptor-deficient mice. Br. J. Pharmacol., 138, 469-480.
133. TUNE, L.E. (2001). Anticholinergic effects of medication in elderly patients. J. Clin. Psychiatry, 62 (Suppl. 21), 11-14.
134. TURNER, W.H. & BRADING, A.F. (1997). Smooth muscle of the bladder in the normal and the diseased state: pathophysiology, diagnosis and treatment. Pharmacol. Ther., 75, 77-110.
135. 4 muscarinic receptor knockout mice. Mol. Psychiatry, 8, 673-679.
136. VAN KERREBROECK, P., KREDER, K., JONAS, U., ZINNER, N. & WEIN, A. (2001). Tolterodine once-daily: superior efficacy and tolerability in the treatment of the overactive bladder. Urology, 57, 414-421.
137. VOLPICELLI, L.A. & LEVEY, A.I. (2004). Muscarinic acetylcholine receptor subtypes in cerebral cortex and hippocampus. Prog. Brain Res., 145, 59-66.
138. WANG, H., HAN, H., ZHANG, L., SHI, H., SCHRAM, G., NATTEL, S. & WANG, Z. (2001). Expression of multiple subtypes of muscarinic receptors and cellular distribution in the human heart. Mol. Pharmacol., 59, 1029-1036.
139. WANG, P., LUTHIN, G.R. & RUGGIERI, M.R. (1995). Muscarinic acetylcholine receptor subtypes mediating urinary bladder contractility and coupling to GTP binding proteins. J. Pharmacol. Exp. Ther., 273, 959-966.
140. 3 muscarinic acetylcholine receptors in mammalian hearts. Br. J. Pharmacol., 142, 395-408.
141. WATSON, E.L., ABEL, P.W., DIJULIO, D., ZENG, W., MAKOID, M., JACOBSON, K.L., POTTER, L.T. & DOWD, F.J. (1996). Identification of muscarinic receptor subtypes in mouse parotid gland. Am. J. Physiol. Cell Physiol., 271, C905-C913.
142. WIEDERHOLT, M., SCHÄFER, R., WAGNER, U. & LEPPLE-WIENHUES, A. (1996). Contractile response of the isolated trabecular meshwork and ciliary muscle to cholinergic and adrenergic agents. German J. Ophthalmol., 5, 146-153.
143. 3-muscarinic receptors in the human heart. Naunyn-Schmiedeberg's Arch. Pharmacol., 368, 316-319.
144. WOLDEMUSSIE, E., FELDMANN, B.J. & CHEN, J. (1993). Characterization of muscarinic receptors in cultured human iris sphincter and ciliary smooth muscle cells. Exp. Eye Res., 56, 385-392.
145. WOMACK, K.B. & HEILMAN, K.M. (2003). Tolterodine and memory: dry but forgetful. Arch. Neurol., 60, 771-773.
146. 3 muscarinic acetylcholine receptor are hypophagic and lean. Nature, 410, 207-212.
147. 5 muscarinic acetylcholine receptor knockout mice. Proc. Natl. Acad. Sci. U.S.A., 98, 14096-14101.
148. YONO, M., YOSHIDA, M., TAKAHASHI, W., INADOME, A. & UEDA, S. (2000). Comparison of the effects of novel antimuscarinic drugs on human detrusor smooth muscle. BJU Int., 86, 719-725.
149. YOSHIDA, M., MIYAMAE, K., IWASHITA, H., OTANI, M. & INADOME, A. (2004). Management of detrusor dysfunction in the elderly: changes in acetylcholine and adenosine triphosphate release during aging. Urology, 63 (3 Suppl. 1), 17-23.
150. ZHOU, H., MEYER, A., STARKE, K., GOMEZA, J., WESS, J. & TRENDELENBERG, A.U. (2002). Heterogeneity of release-inhibiting muscarinic autoreceptors in heart atria and urinary bladder: a study with M(2)- and M(4)-receptor-deficient mice. Naunyn-Schmiedeberg's Arch. Pharmacol., 365, 112-122.
151. 3 SRA), compared with oxybutynin in the treatment of patients with overactive bladder. World J. Urol., 23, 248-252.